FDA Approves LENALIDOMIDE — Teva Pharmaceuticals, Inc.

# FDA Approves Generic Lenalidomide; Teva Pharmaceuticals Poised to Capture Market Share The FDA has approved Teva Pharmaceuticals' generic version of Lenalidomide (ANDA 201452), opening the door for significant price competition in the multiple myeloma and myelodysplastic syndrome markets currently dominated by Celgene's brand-name product. The approval is expected to drive down treatment costs and expand patient access while potentially pressuring revenues for branded lenalidomide manufacturers.